Ascendis PharmaASND
Recorded

Ascendis Pharma Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Faisal KhurshidSenior Biotech Analyst

All right. Good morning, everyone. Thank you for joining us here in nice and rainy London. My name is Faisal Khurshid. I am one of the Senior Biotech Analysts here at Jefferies. Really pleased to have with us today management team of Ascendis Pharma. I have on stage with me Jan Mikkelsen, CEO, Scott Smith, CFO of the company. Let us get right to it. I mean, you guys just reported nice third quarter earnings last week. You have two growth products. Maybe we can just start with some of the highlights from earnings. I do not know if, Jan, if you want to start or Scott.

Jan MikkelsenCEO

I think Scott should start today.

Scott SmithCFO

Start with the question or start with the FLS?

Scott SmithCFO

The question. Okay. Yeah, thanks for the invitation for the conference here, and it is a really neat setting to see everybody packed in here.

Scott SmithCFO

As you alluded to, we just reported our Q3 results last week, so the conference is timely. We had pretty good revenue growth, I would say, 90% or so year-over-year to EUR 366 million. Strong growth across the portfolio. We also announced, which Jan, I am sure will be interested to go into detail on, and across from the OPEX perspective, we had about EUR 230 million of OPEX leading to pretty good, I would say almost industry-leading operating margins of the low 40s, 40% or so.

Scott SmithCFO

But, I think more importantly, we laid out also a vision in the prepared remarks about how we as a company develop from where we are today to get to EUR 5 billion of revenue by 2030, EUR 10 billion by 2035, and sustain double-digit top-line growth in the preceding years, or in the years after.

Faisal KhurshidSenior Biotech Analyst

Got it. Jan, maybe on that point, you put out this pretty aspirational long-term vision of the, Scott Smith mentioned the EUR 5 billion by 2030, EUR 10 billion by 2035. I think Wall Street mostly loves you, but is not quite there on that aspiration. Can you comment where you see people underappreciating the potential relative to what you see?

Jan MikkelsenCEO

I think first, let us recall a little bit about our drivers. We made one driver that basically giving us the EUR 5 billion in 2030. This driver is built on our three approved product, SKYTROFA, YORVIPATH, and YUVIWEL, in already approved indications. We will still have geographic expansion of our product opportunities. Currently, for example, for YORVIPATH, we have about 13 countries where we fully commercial. We recognize revenue for about 40, but we also know that first, when we fully commercial, we are really getting first the real revenue driver. These 30 countries will grow with additional 15 in 2028, additional 10, 15 in 2029. That is what we call the first driver. So when we think about the EUR 5 billion, there is only one thing that is differences, how really do you do your forecasting?

Jan MikkelsenCEO

And if you just follow the guidance that have been given by Scott and me again and again, it is really simple. We see a really constantly growth in YORVIPATH in the U.S., where we every quarter is adding little bit more than 1,000 new prescriptions. We also seeing an ex-U.S. growth that have been accelerated quarter by quarter. This acceleration will be accelerated further as when I said we get more and more countries fully commercial. You also see YUVIWEL coming in. In less than two quarter, it basically took half of the number patient in the U.S. before we launch to YUVIWEL treatment, really showing how it is highly differentiated. It is a treatment regime that provide benefit to the patient where you really address the comorbidities, not only giving height. So that was the first driver. Then Scott come in and talked about the EUR 10 billion in 2035.

Jan MikkelsenCEO

It is coming still for the existing three product, SKYTROFA, YORVIPATH, and YUVIWEL. But we adding in all the established label expansion we have, both as monotherapy, but also as combination therapy. Just take SKYTROFA. SKYTROFA is going to be a blockbuster too. We only have half of the daily growth hormone indication now on labeling. We have started all the trial, nearly all of them are fully enrolled, to get all the indication they have on daily growth hormone. In addition, as the only product, we now pursuing additional indication like combination treatment in achondroplasia, combination treatment in hypochondroplasia. Going to YORVIPATH, label expansion is nearly Coming to a stage where all the patients are enrolled for U.S., increasing the dose from 30 up to 60, giving 10%-15% more revenue, basic without more patients.

Jan MikkelsenCEO

We are enrolling in two clinical trials, one in U.S., one ex-U.S., to patient down to 12, which also will be fully enrolled next year. We, on the same time, are trying to find out how can we really help the patients that not have the diagnosis of chronic hypoparathyroidism, but just got the initial characteristic of missing and not having enough endogenous PTH. For YORVIPATH, we have label expansion, for example, going down to a newborn, all the patient has been enrolled. The pivotal trial will read out next year. We are in a position that we, as the first one, went into adult achondroplasia, running an exploratory phase II to find out how we can also help these patients.

Jan MikkelsenCEO

At the same time, we starting what we call a complete new treatment regime for achondroplasia, where we see effect that never have been described with therapeutic intervention with the combination therapy between YORVIPATH and SKYTROFA. Open up for a new treatment regime where we really can address the underlying comorbidities for this patient group, so the potential can avoid all kind of surgeries. Complete new treatment regime. All that is part of hitting the EUR 10 billion in 2035. It is really clear, all this trial is started. We need to finalize them, but we also have shown how we are really are progressing with all our clinical development, regulatory approval, launching pretty successful. Currently today, we have treated more than 30,000 patients with TransCon products, and we continue this trend.

Jan MikkelsenCEO

We both have the scalability as a company, the global reach that we are building up to be the big pharma company we want to be. When we come past in the third driver, this is the new product opportunities, and we continue to develop new product opportunity with the TransCon technology, not only in rare disease endocrine, where we now have opportunity to work on all different possibilities, but also in outside rare disease. We want to build up a new therapeutic area, as we did in rare disease endocrine. It will be built up in the same way, not a single product, three to four unique product, where each of them are highly differentiated, addressing a major unmet medical need, but at the same time also have the potential to be a major blockbuster. YORVIPATH, we made a blockbuster in 18 months, both in EUR or dollars.

Jan MikkelsenCEO

I prefer EUR. But out from that perspective is that this is our aspiration for each single product. Perhaps we will not do all of them in 18 months. We will perhaps use two, three, four years, but it also okay in my perspective. We can live with that, as long as we really address an unmet medical need, and that is true. When people saying, "Oh, there's a difference between street or research, but you're part of research," I do not know what you do wrong in your calculation. Because it's pretty simple when we run the numbers. We can run them in a lot of different ways. What is you? Oh, man.

Faisal KhurshidSenior Biotech Analyst

I feel like I kind of poked the bear here.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day